NCT05957380

Clinical Study to Evaluate the Efficacy and Safety of DA-2803 in Chronic Hepatitis B Patients

A Multicenter, Double-blind, Active-controlled, Randomized, Parallel Clinical Study to Evaluate the Efficacy and Safety of DA-2803 in Chronic Hepatitis B Patients

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 120 (actual)
• Sponsor: Dong-A ST Co., Ltd. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

This study is a multi-center, double-blind, active-controlled, randomized, parallel clinical study to evaluate the efficacy and safety of DA-2803 in chronic hepatitis B subjects

Conditions

• Hepatitis B

Interventions

Type	Name	Description
DRUG	DA-2803	All participants are administered one tablet per day for 48 weeks
DRUG	DA-2803-R	All participants are administered one tablet per day for 48 weeks
DRUG	Placebo of DA-2803	All participants are administered one tablet per day for 48 weeks
DRUG	Placebo of DA-2803-R	All participants are administered one tablet per day for 48 weeks

Timeline

• Start date: 2023-03-20
• Primary completion: 2024-09-30
• Completion: 2024-09-30
• First posted: 2023-07-24
• Last updated: 2024-10-23

Locations

1 site across 1 country: South Korea